Charles River Q3 revenue $989.2M (+10.4% YoY); raises guidance, plans Avian Vaccine sale for ~$170M

CHARLES RIVER LABORATORIES INTERNATIONAL, INC.

2022-Q3 EPS reported $5.83 revenue$2,876,217,000

Q3 revenue $989.2M (+10.4% YoY, organic +15.3%); GAAP EPS $1.88 (-6.5%), non-GAAP EPS $2.63 (-2.6%).
DSA segment revenue $619.5M (+16.5%) drove results; Manufacturing declined -1.7% to $189.6M.
Narrows 2022 guidance: reported revenue growth 10-11%, non-GAAP EPS $10.80-10.95 (prior $10.70-10.95).
Announced divestiture of Avian Vaccine business for ~$170M cash plus up to $30M contingent; close expected by year-end.
Divestiture to reduce 2023 revenue by ~$80M and non-GAAP EPS by ~$0.35 before redeployment of proceeds.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. reported third quarter ended September 24, 2022 results: revenue $989.2 million, net income $96.5 million, EPS $1.88. Guidance reaffirmed.

Period: third quarter ended September 24, 2022
Revenue: $989.2 million
Net income: $96.5 million
EPS: $1.88
Guidance: reaffirmed
Result: reported results

Exact text from the filing

EX-99.1 (EXHIBIT 99.1) --- EX-99.1 2 a52958171ex99_1.htm EXHIBIT 99.1 Exhibit 99.1 Charles River Laboratories Announces Third-Quarter 2022 Results – Third-Quarter Revenue of $989.2 Million – – Third-Quarter GAAP Earnings per Share of $1.88 and Non-GAAP Earnings per Share of $2.63 – – Narrows 2022 Revenue Growth and Earnings Per Share Guidance – – Announces Planned

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

CHARLES RIVER LABORATORIES INTERNATIONAL, INC. filing history →

Source: SEC EDGAR

accession 0001157523-22-001470

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.